

PE anti-mouse/human CD11b

Catalog # / Size: 1106040 / 200 µg
1106035 / 50 µg

Clone: M1/70

Isotype: Rat IgG2b, κ


Immunogen: C57BL/10 splenocytes

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Concentration: 0.2




C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram) (gated on total cells).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 microg per 10^6 cells in 100 microl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: Additional reported applications (for relevant formats of this clone) include: immunoprecipitation^{1,4}, *in vitro* blocking^{3,9,12}, depletion^{2,8}, immunofluorescence microscopy^{6,7,10}, and immunohistochemistry of acetone-fixed frozen sections^{5,11-13} and paraffin sections²⁸. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 101231). For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 101248) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/microg).



Fixed whole mount mouse spleen was stained with Alexa Fluor® 488 F4/80 (red) (clone BM8), Brilliant Violet 421™ CD3ε (green) (clone 145-2C11), and PE CD11b (blue) (clone M1/70). Isotype controls at the same concentrations were used for

- Application References:**
1. Springer T, *et al.* 1978. *Eur. J. Immunol.* 8:539. (IP)
 2. Ault K and Springer T. 1981. *J. Immunol.* 126:359. (Deplete)
 3. Springer TA, *et al.* 1982. *Immunol. Rev.* 68:171. (Block)

4. Ho MK and Springer TA. 1983. *J. Biol. Chem.* 258:2766. (IP)
5. Flotte TJ, *et al.* 1983. *Am. J. Pathol.* 111:112. (IHC)
6. Noel GJ, *et al.* 1990. *J. Clin. Invest.* 85:208. (IF)
7. Allen LA and Aderem A. 1996. *J. Exp. Med.* 184:627 (IF)
8. D'Amico A and Wu L. 2003. *J. Exp. Med.* 198:293. (Deplete)
9. Brickson SJ, *et al.* 2003. *Appl Physiol.* 95:969. (Block)
10. Clatworthy MR and Smith KG. 2004. *J. Exp. Med.* 199:717. (IF)
11. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
12. Zhang Y, *et al.* 2002. *J. Immunol.* 168:3088. (IHC)
13. Iwasaki A and Kelsall BL. 2001. *J. Immunol.* 166:4884 (IHC, FC)
14. Tailleux L. 2003. *J. Exp. Med.* 197:121. (Block, FC)
15. Olver S, *et al.* 2006. *Cancer Research* 66:571. (FC)
16. Tan SL, *et al.* 2006. *J. Immunol.* 176:2872. (FC) [PubMed](#)
17. Ponomarev ED, *et al.* 2006. *J. Immunol.* 176:1402. (FC)
18. Dzhagalov I, *et al.* 2007. *Blood* 109:1620. (FC)
19. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
20. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. [PubMed](#)
21. Napimoga MH, *et al.* 2008. *J. Immunol.* 180:609. [PubMed](#)
22. Elqaraz-Carmon V, *et al.* 2008. *J. Lipid. Res.* 49:1894. [PubMed](#)
23. Kim DD, *et al.* 2008. *Blood* 112:1109. [PubMed](#)
24. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
25. Norian LA, *et al.* 2009. *Cancer Res.* 69:3086. (FC) [PubMed](#)
26. Baumgartner CK, *et al.* 2010. *J. Immunol.* 184:573. [PubMed](#)
27. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
28. Whiteland J, *et al.* 1995. *J. Histochem. Cytochem.* 43:313. (IHC)
29. Hirako N, *et al.* 2014. *PLoS One.* 9:103282. [PubMed](#)
30. Garcia-Bonilla L, *et al.* 2014. *J Immunol.* 193:2531. [PubMed](#)
31. Textor A, *et al.* 2014. *Cancer Res.* 74:6796. [PubMed](#)
32. Jaworska J, *et al.* 2015. *J Immunol.* 194:325. [PubMed](#)
33. Xiao Z, *et al.* 2015. *Cancer Lett.* 360:302. [PubMed](#)
34. Li X, *et al.* 2015. *PNAS.* 112:6080. [PubMed](#)
35. Sharma SK, *et al.* 2015. *J Immunol.* 194:5529.

Description: CD11b is a 170 kD glycoprotein also known as α M integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β 2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

Antigen 1. Barclay A, *et al.* 1997. The Leukocyte Antigen FactsBook
References: Academic Press.
 2. Springer TA. 1994. *Cell* 76:301.
 3. Coxon A, *et al.* 1996. *Immunity* 5:653.